In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Showing 1 to 9 of 9

TitleTypeExpected publication date
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]Technology appraisal guidance
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]Technology appraisal guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513Technology appraisal guidanceTBC
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All